It is now accepted that activation of Class I PI3Ks (phosphoinositide 3-kinases) is one of the most important signal transduction pathways used by cell-surface receptors to control intracellular events. The receptors which access this pathway include those that recognize growth factors, hormones, antigens and inflammatory stimuli, and the cellular events known to be regulated include cell growth, survival, proliferation and movement. We have learnt a great deal about the family of Class I PI3K enzymes themselves and the structural adaptations which allow a variety of cell-surface receptors to regulate their activity. Class I PI3Ks synthesize the phospholipid PtdIns(3,4,5)P 3 in the membranes in which they are activated, and it is now accepted that PtdIns(3,4,5)P 3 and its dephosphorylation product PtdIns(3,4)P 2 are messenger molecules which regulate the localization and function of multiple effectors by binding to their specific PH (pleckstrin homology) domains. The number of direct PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 effectors which exist, even within a single cell, creates an extremely complex signalling web downstream of PI3K activation. Some key players are beginning to emerge, however, linking PI3K activity to specific cellular responses. These include small GTPases for the Rho and Arf families which regulate the cytoskeletal and membrane rearrangements required for cell movement, and PKB (protein kinase B), which has important regulatory inputs into the reguKey words: cell-surface receptor, Class I phosphoinositide 3-kinase (Class I PI3K), phosphoinositide, pleckstrin homology domain (PH domain), PtdIns(3,4,5)P3, signalling. Abbreviations used: BCR, B-cell receptor; EGF, epidermal growth factor; fMLP, Nformylmethionyl-leucylphenylalanine; GEF, guanine nucleotide-exchange factor; GFP, green fluorescent protein; IRS, insulin receptor substrate; KD, kinase dead; mTORC, mammalian target of rapamycin complex; PDGF, platelet-derived growth factor; PDK, phosphoinositide-dependent kinase; PH, pleckstrin homology; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PTEN, phosphatase and tensin homologue deleted on chromosome 10; PX, phox homology; SH2, Src homology 2; SHIP, SH2-containing inositol phosphatase. 1 To whom correspondence should be addressed (email Phillip.Hawkins@bbsrc.ac.uk).
Introduction
This review will attempt to concisely summarize our current understanding of the Class I PI3K (phosphoinositide 3-kinase) signalling system in mammalian cells, including what we know of the PI3K enzymes themselves, some examples of the molecular mechanisms which are thought to operate in their activation by cell-surface receptors, the paradigms that exist for their lipid products to act as effectors of this pathway, and an overview of the physiological processes in which this cell signalling system is thought to play a particularly major role. We shall also attempt to summarize available information on how to study this pathway in a given context of cellular regulation.
PI3K activities
PI3Ks are a family of enzymes that were originally defined on the basis that they could catalyse the phosphorylation of the 3-position of the inositol ring in one or more phosphoinositide substrates [1, 2] . The nomenclature and structure of the phosphoinositide species found in mammalian cells and the reactions catalysed by PI3Ks are summarized in Figures 1  and 2 .
Through classical biochemical purification and DNAhomology-based approaches, several PI3K activities have now been characterized at the molecular level [3] . Our current understanding of the genes encoding the catalytic and regulatory subunits of these enzymes and a comparison of their conserved domains are summarized in Figure 3 . Each of the Schematic structures are shown for the eight different phosphoinositides found in mammalian cells, together with the abbreviations for these molecules commonly found in the literature. The relative abundance of fatty acids which are esterified to the glycerol moiety in these lipids is largely unknown; 1, stearoyl; 2, arachidonyl, is depicted on the basis of the very limited information available [69, 70] .
Figure 2 Reactions catalysed by PI3K activities in vitro
The three reactions commonly ascribed to PI3K activities in vitro are shown. In each case, the PI3K activity transfers phosphate from ATP to the 3-position of the inositol headgroup in the phosphoinositide substrate.
catalytic subunits of these enzymes share substantial homology in their lipid kinase domains, but differ greatly in other domains and in their regulatory subunits. On the basis of their structural and functional homologies, they have been classified into three major 'Classes' or 'Types': I, II and III.
The Class I PI3Ks are tightly bound heterodimers of four closely related approx. 110 kDa catalytic subunits and two distinct families of regulatory subunits, which form the basis of their further subdivisions into Class IA and IB. The Class IA enzymes are dimers of p110α, p110β or p110δ catalytic subunits and p50-55/p85 regulatory subunits. The Class IB enzymes are dimers of the p110γ catalytic subunit and either p101 or p84 (also known as p87 PIKAP ) regulatory subunits. Thus far there is little compelling evidence that within the IA and IB subdivisions there are any significant preferences for specific catalytic subunit/regulatory subunit pairs. This is one of the reasons that the classification of a 'PI3K isoform' in the literature tends to refer only to the identity of the catalytic subunit present in the dimer, e.g. PI3Kβ refers to dimers containing p110β and, it is assumed, one of the p50-55/p85 family of regulatory subunits; likewise, PI3Kγ refers to a dimer of p110γ and either p101 or p84. As work progresses which starts to unravel the specific functions of the individual regulatory subunits, then it is likely that the nomenclature will need to become more tightly defined and include reference to both subunits, e.g. p84/p110γ compared with p101/p110γ .
Pathways of phosphoinositide metabolism
There has been much debate and confusion in the literature over the years as to the true physiological substrates of PI3Ks, particularly the Class I enzymes. This is due in part to the difficulties in presenting phospholipid substrates in a physiologically relevant manner in vitro (i.e. in the absence of biological membranes) and the difficulties in defining specific routes of metabolism within complex metabolic pathways in vivo. The currently accepted consensus for the reactions catalysed by Class I, II and III PI3Ks in intact cells is presented within the known context of phosphoinositide metabolism in Figure 4 .
Class I enzymes are now generally considered to preferentially phosphorylate PtdIns(4,5)P 2 and hence synthesize Schematic domain structures for the regulatory and catalytic subunits which comprise the known PI3K activities measured in vitro and in vivo are shown, together with the nomenclature of the proteins and the genes encoding them [3, 7, 47] . They are grouped into three Classes or Types on the basis of the levels of homology between the relevant catalytic subunits. The Class IA enzymes are heterodimers of one p85 or p50-55 regulatory subunit and one of three possible catalytic subunits (p110α, p110β or p110δ). The Class IB enzymes are heterodimers of either a p101 or p84 regulatory subunit and a p110γ catalytic subunit. The Class II enzymes (IIα, IIβ or IIγ ) are not known to have tightly bound regulatory subunits. The only Class III enzyme is thought to be a heterodimer of a p150 protein kinase and the mammalian homologue of the yeast VPS34 PI3K.
Figure 4 Pathways of phosphoinositide metabolism
The major routes of phosphoinositide metabolism thought to operate in mammalian cells are depicted. Where known, the main enzyme activities thought to catalyse these conversions are also noted, together with the number of gene products encoding them (shown as oval symbols; homologues are shown as touching symbols). The activation of Class I PI3Ks by cell-surface receptors is shown, leading to the rapid synthesis of PtdIns(3,4,5)P 3 and, via the action of 5-phosphatases, the synthesis of PtdIns(3,4)P 2 . MTM, myotubularin; MTMR, MTM-related protein; P'tase, phosphatase.
PtdIns(3,4,5)P 3 . The clarity with which Class I and Class III PI3Ks are considered to synthesize PtdIns(3,4,5)P 3 and PtdIns3P respectively is supported by a now huge body of data linking these enzymes to the role of their distinct lipid products in separate areas of metabolic regulation. Thus Class I PI3K-generated PtdIns(3,4,5)P 3 represents a major signal transduction pathway downstream of cell-surface receptors [2, 3] , which is the subject of this review. Class III PI3K-generated PtdIns3P represents a major regulatory pathway defining and controlling the passage of proteins and membranes through the endosomal/lysosomal compartments [4] . Unfortunately, the same level of knowledge is not yet available for the Class II enzymes, although evidence is mounting that they are likely to represent an alternative route for phosphorylation of PtdIns to form PtdIns3P in certain contexts of cell-surface receptor activation and/or endocytosis [5, 6] .
Activation of Class I PI3Ks by cell-surface receptors
A large body of data now links the activation of a wide variety of cell-surface receptors to the stimulation of Class I PI3Ks in target cells. This includes receptors for the majority of growth factors and many inflammatory stimuli, hormones, neurotransmitters and antigens, and thus the activation of PI3Ks represents one, if not the most prevalent, signal transduction event associated with mammalian cell-surface receptor activation [1] [2] [3] 7] .
Measurement of the changes in levels of the phosphoinositide products of activated Class I PI3Ks is relatively technically demanding, and, despite several attempts to develop alternative assays, [ 32 P]P i -labelling, lipid extraction, deacylation and quantification of PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 headgroups by anion-exchange HPLC still represent the most accurate way of assessing Class I PI3K activity in cells ( Table 1) . As a consequence, there are remarkably few studies of changes in PtdIns(3,4,5)P 3 levels after appropriate cell stimulation. More often, activation of Class I PI3K is inferred by the activation of accepted effectors in this pathway [e.g. phosphorylation of PKB (protein kinase B); see below], some change in the properties of a Class I PI3K itself (e.g. its association with signalling complexes, most often the appearance of Class IA protein or activity in phosphotyrosine-directed immunoprecipitates; see below), or the change in a cellular response caused by inhibition of Class I PI3K activity (created via either genetic approaches or addition of a catalytic site inhibitor; see below). Where direct Link between inhibition of PI3K activity and cellular response Indirect assessment of activity (i) Genetic approaches Mouse transgenics (see Table 3 ) Expression of p85 dominant-negative construct (ii) Catalytic site inhibitors (see Table 4 ) measurements of phosphoinositide levels have been performed, however, the qualitative pattern of changes in the PI3K products under quite different contexts of cell stimulation are remarkably similar ( Figure 5 ). The salient points are that most 'basal' mammalian cells contain significant quantities of PtdIns3P, synthesized by Class III and probably Class II PI3Ks, and very low quantities of PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 . Upon appropriate stimulation, the levels of PtdIns(3,4,5)P 3 rise dramatically, followed by accumulation of PtdIns(3,4)P 2 after a lag. The speed and extent of PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 accumulations depend upon the context of cell stimulation and, in particular, on the nature of the proximal signal transducing mechanism of the activated receptor, but always appear to represent a significant fold increase over basal levels. These rapid rises in the immediate products of activated Class I PI3Ks were the first clues that PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 were likely to be the primary signals generated by this pathway [2] .
Receptor coupling to Class IA PI3Ks
Significant progress has been made in understanding the molecular mechanisms which allow activation of Class I PI3Ks downstream of various receptor types (summarized in Figure 6 ) [1, 7] . Class IA heterodimers are adapted to receive regulatory inputs from receptors utilizing the activation of protein tyrosine kinases as their proximal signal transducing elements. The protein tyrosine kinases involved can be integral to the receptor itself, as is the case in many growth factor receptors [e.g. receptors for PDGF (platelet-derived growth factor), EGF (epidermal growth factor) and IGF (insulinlike growth factor); see Figure 6A ] or activated by direct or indirect association with the receptor [e.g. members of the Syk/ZAP70 (T-cell receptor ζ -chain-associated protein kinase of 70 kDa) or Src family of protein tyrosine kinases associating with antigen or antibody receptors]. These tyrosine kinases are able to phosphorylate critical tyrosine residues within so-called activation motifs, which can be present on the receptors themselves (e.g. PDGF or Fc receptors) or present on receptor-associated proteins, often called adaptors [e.g. IRS (insulin receptor substrate), Gab and Cbl). By virtue of their local amino acid sequence, these phosphotyrosine residues can then act as binding ligands for specific SH2 (Src homology 2)-domain-containing effector molecules. Phosphotyrosine residues within so-called YXXM (Tyr-XaaXaa-Met) motifs can bind with high affinity to one or both of the SH2 domains in the p85/p50-55 regulatory subunits in Class IA PI3Ks, leading to their recruitment into receptor signalling complexes. It is becoming increasingly clear that many receptor signalling complexes are often quite large and that several layers of co-operative regulation are involved in their assembly, including the products of Class I PI3K NIH 3T3 cells or human neutrophils were pre-labelled with [ 32 P]P i and then stimulated with PDGF or fMLP, two agonists established to activate Class IA or Class IB PI3Ks in these cells respectively. 32 P-Labelled lipids were extracted and the relevant [ 32 P]phosphoinositides were quantified by deacylation and anion-exchange chromatography [71, 72] .
activity themselves [see Figure 7 for an example of this complexity downstream of BCR (B-cell receptor)/CD19 engagement in B-cells]; thus several signalling enzymes also perform scaffolding or adaptor roles in addition to what was considered to be their main enzymic function (this level of complexity can make the interpretation of gene-deletion studies particularly difficult).
Once recruited, the mechanisms leading to activation of Class IA PI3Ks in signalling complexes are poorly understood. A major factor is likely to be the change in effective substrate concentration on moving from a soluble/cytoplasmic location to close proximity to the membrane [i.e. close to PtdIns(4,5)P 2 ]. Other factors are likely to include SH2-phosphotyrosine docking, leading to the relief of a p85-mediated constraint on the p110 catalytic subunit's activity, an event possibly mimicked by activating oncogenic mutations in the p85-binding site of p110α [8, 9] . A further important element governing the activity of Class IA PI3K in these signalling complexes is the direct association of the GTP-bound form of Ras with an RBD (Ras-binding domain) motif in the p110 catalytic subunit [10, 11] . Activation of Ras by guanine nucleotide exchange of GDP for GTP is a key signalling event downstream of many different receptor types, which often occurs in parallel with Class I PI3K activation and is most often associated with the activation of ERK (extracellular-signal-regulated kinase) family protein kinase cascades regulating cell growth and division [12] . Some of the clearest evidence defining the ability of GTP-Ras to interact with and activate Class I PI3Ks has come from the study of Ras binding to p110γ (see below), but there is also strong evidence that Ras plays a key role in activating PI3Kα and PI3Kδ, although interestingly, not PI3Kβ [13] . [1, 3, 7, 73] . A schematic representation of the activation of Class IA heterodimers by a growth factor receptor with intrinsic protein tyrosine kinase activity is shown. The key features are growth-factor-induced dimerization of the receptor, transphosphorylation (·-·-·) of multiple key tyrosine residues in the cytoplasmic tails, which act as docking sites ( ) for multiple SH2-domain-containing signalling proteins. Some of these phosphotyrosine residues are within YXXM motifs that act as docking sites for the SH2 domains in the p50-55 or p85 regulatory subunits of Class IA PI3Ks, leading to their recruitment into these growth factor receptor signalling complexes. GTP-Ras is known to bind to the catalytic subunit of Class I PI3Ks and is thought to play a role in the synergistic activation of their lipid kinase activity [10, 11] . Ras is converted into the GTP bound form by GEFs (----), which are often recruited in parallel to PI3Ks by distinct phosphotyrosine residues in these signalling complexes (in the example shown, the Ras GEF, SOS, is recruited indirectly via the adaptor GRB2) [12] . (B) Activation of Class IB PI3K by receptors utilizing heterotrimeric G-proteins as their proximal signal transduction element.
A schematic representation of the activation of a heterodimer of either p101 or p84 regulatory subunits and the p110γ catalytic subunit by a G i -coupled receptor is shown. Key features are the direct binding and activation of the Class IB PI3K by G βγ s that are liberated by dissociation of the heterotrimeric G-protein; the precise binding site for the G βγ s is unknown, but the p101 [18] or p84 [27, 28] regulatory subunit is known to be required for significant activation. GTP-Ras is known to bind directly to p110γ [25] , and recent evidence indicates this interaction plays an important role in activation of the PI3K activity downstream of G i -coupled receptors [26] ; the mechanism by which guanine nucleotide exchange on Ras is stimulated in these contexts of receptor activation is, however, unknown.
Figure 7 The signalosome downstream of antigen stimulation of B-cells
Schematic representation of the complex interactions which are thought to form a signalling complex (the so-called 'signalosome') after presentation of antigen to B-cells [73, 74] . Many of the phosphorylations (·-·-· and -··-) and SH2 domain docking ( ) interactions, are drawn from data which suggest that they can occur under some circumstances, but the relative importance of many of these in vivo is still to be established. However, some features are clear. Activation of the BCR by MHC/antigen leads to activation of the Src family kinase Lyn, leading to tyrosine phosphorylation of ITAMs (immunoreceptor tyrosine-based activation motifs) in the receptor tails and SH2-domain-mediated recruitment and activation of the tyrosine kinase Syk. Syk and Lyn are thought to be responsible for tyrosine phosphorylation of additional adaptors and signalling molecules that lead ultimately to the regulation of B-cell activation and clonal expansion. Co-ligation of the CD19 receptor is known to dramatically increase the signals generated by BCR engagement by providing additional docking sites and signalling molecules that are thought to potentiate the formation of the signalosome. Relevant here is that Class IA PI3Ks are recruited via SH2 domain docking on to CD19, and the PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 generated is thought to recruit and potentate Btk-mediated phosphorylation and activation of PLCγ 2 , which is responsible for the InsP 3 -mediated increases in cell Ca 2+ concentration, which are critical for subsequent signal propagation. PIPK1, phosphatidylinositol phosphate kinase.
Given the central importance of Ras-and Class IA PI3K-directed signalling pathways in the regulation of cell growth and division, the direct interaction between them in signalling complexes downstream of growth factor receptors is likely to be a very important axis through which these cell fates are regulated (see below). In addition to its lack of sensitivity to Ras, other observations also suggest that PI3Kβ may be regulated differently to the other Class IA isoforms; it can be activated by G βγ in synergy with p85-phosphotyrosine docking [14] and it appears to be a direct effector of Rab5, indicating a possible role in endocytosis [15] .
Although the role of the p85/p50-55 regulatory subunits in activating Class IA PI3Ks is undisputed, it is becoming clear that p85 subunits may also have additional functions. Deletion of various combinations of the genes encoding the p85/p50-55 subunits in the mouse resulted in paradoxical increases in the apparent sensitivities of PI3K-dependent pathways downstream of insulin receptors (see Table 3 for references). Recent evidence suggests that, whereas some level of Class IA PI3K activity is necessary for many of insulin's actions, higher levels of p85 negatively regulate the pathway through activation of PTEN (phosphatase and tensin homologue deleted on chromosome 10) [16] or, via competition between free subunits and heterodimers for limiting numbers of activating phosphotyrosine residues on adaptors such as IRS1 [17] .
Receptor coupling to Class IB PI3Ks
Class IB heterodimers are activated by cell-surface receptors utilizing heterotrimeric G-proteins as their proximal signal transduction event (see Figure 6B) . The p101/p110γ heterodimer can be activated directly by binding G βγ subunits in vitro [18] , and p110γ is required for significant activation of PtdIns(3,4,5)P 3 production by G i -coupled receptors in mouse myeloid cells in vivo [19] [20] [21] . The mechanism of activation by G βγ is unknown, but is highly dependent on the presence of p101 and probably involves both allosteric and localization elements [22, 23] . The p110γ catalytic subunit has also been shown to interact with GTP-Ras and to cause modest activation of its catalytic activity in vitro [24] . A crystal structure is available for a small N-terminal truncation of p110γ in complex with GTP-Ras, which provides some clues as to how GTP-Ras might activate p110γ [25] . Recently, the creation of both p101 −/− mice and also mice with knock-in mutations in p110γ which specifically eliminate GTP-Ras binding, has allowed an assessment of the relative contributions of both G βγ and Ras to the regulation of PI3Kγ ; at least in the case of fMLP (N-formylmethionylleucylphenylalanine) and C5a receptors in neutrophils, it appears both contribute substantially, even at very early times of stimulation [26] .
Recently, a homologue of the p101 regulatory subunit has been discovered, p84 [27] also known as p87 PIKAP [28] . p84 appears to play a similar role to p101 in allowing G βγ s to activate PI3Kγ heterodimers, but the distinct features of these two subunits and the relative roles they play in physiological activation of PI3Kγ have yet to be elucidated.
Several reports suggest Class I PI3Ks are sensitive to a feedback loop involving Rho family GTPases, which may be important in the regulation of cell polarity [29] , although whether this effect is direct or involves Class IA or B PI3Ks is currently unclear.
PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 regulate the activity of multiple effector proteins
There is now overwhelming evidence that PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 are the major signals that are generated by activation of Class I PI3Ks [1] [2] [3] 7] . There are some intriguing data that Class I PI3Ks might also act as protein kinases and may transduce signals via protein kinase cascades [30] , but this has yet to gain general acceptance. It is also likely that PI3Ks will perform additional protein-protein interactions or scaffold functions in signalling complexes (see above), e.g. PI3Kγ is thought to bind cAMP phosphodiesterase in the heart, independent of its lipid kinase activity [31] , possibly via p84/p87 PIKAP [28] .
Work from a large number of laboratories has steadily built the concepts that (i) some PH (pleckstrin homology) domains bind phosphoinositides, (ii) a subset of these PH domains bind PtdIns(3,4,5)P 3 and/or PtdIns(3,4)P 2 with high affinity and specificity, and (iii) several proteins which contain these PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 -specific PH domains play key roles in mediating Class I PI3K-dependent regulation of important cellular responses. Thus a paradigm has emerged for how the Class I PI3K pathway operates as a signalling system, which is described in Figure 8 . A key feature of this model is that rises in PtdIns(3,4,5)P 3 / PtdIns(3,4)P 2 are interpreted by multiple primary effectors and thus have an extended influence on a very large signalling net or web (it is estimated that there are upwards of 20 such effectors in any particular cell type [32] ).
In most cases, it is still unclear precisely how PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 engagement with the PH domain of an effector protein regulates its activity. In several cases, this interaction is of sufficient affinity that the target protein undergoes a net change from a predominantly cytosolic to a predominantly plasma membrane location, widely referred to as a plasma membrane 'translocation' (Figure 9 ). Indeed, when fused to a fluorescent protein tag, such as GFP (green fluorescent protein), these PI3K-dependent translocations are often used as evidence that a particular PH domain or protein is acting as a PI3K effector, and, once established, as a measure of Class I PI3K activity itself. It is thought that these translocation events are 'activating', in the sense that target proteins are brought into proximity with substrates or binding partners. It is also becoming clear, however, that PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 binding to PH domains can often derepress an intramolecular inhibition mediated by the PH domain, causing significant activation of the effector. It is probably the case that both of these types of mechanisms operate to some extent in most cases. For example, in the activation of GEFs (guanine nucleotideexchange factors) for small GTPases, PtdIns(3,4,5)P 3 binding is thought to relieve a PH-domain-mediated inhibition of the Dbl catalytic domain and also bring the GEF into proximity with its lipid-tethered GTPase [33] . Another example is in PDK (phosphoinositide-dependent kinase)-mediated phosphorylation and activation of PKB (also known as Akt) [34] [35] [36] (see Figure 10 ). Both PDK and PKB possess PH domains which bind PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 , allowing an increase in their relative effective concentration on Class I PI3K activation. PDK appears to be 'constitutively active' and its activity is independent of phosphoinositide/PH domain binding; it has a major role in PI3K-independent phosphorylation of the activation loop in several 'AGC family' kinases. In contrast, however, the ability of PDK to phosphorylate PKB in its activation loop is highly dependent on Class I PI3K activity; this is because PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 binding to the PH domain of PKB is required to make Thr 308 in the activation loop available for phosphorylation by PDK.
PtdIns(3,4,5)P 3 can be dephosphorylated at the 5-position by SHIP (SH2-containing inositol phosphatase) family phosphatases to produce PtdIns(3,4)P 2 , and at the 3-position PH domains with the appropriate affinity and specificity, leading to their activation [39, 40, 75, 76] . {*PtdIns (3, 4, 5 )P 3 may be sensed by the DHR domain rather than the PH domain in the DOCK180/ELMO complex [77] }. These PH-domain-containing effectors belong to several different protein families, some of which are shown, together with specific examples and an indication of the downstream responses that they are thought to regulate [1, 3, 7, 47] . by PTEN to produce PtdIns(4,5)P 2 . In principle, these two alternative routes of PtdIns(3,4,5)P 3 removal could exist to allow significantly different types of regulation of PtdIns(3,4,5)P 3 signal termination and/or to use PtdIns(3,4)P 2 as an additional signal. Current evidence suggests both are likely to be true. SHIPs are known to be recruited by 'inhibitory receptors' in the immune system via SH2-domain-docking mechanisms [37] (Figure 7) , and PTEN has been suggested to be regulated by catalytic site cysteine oxidation [38] . Some PH domains have specificity for both PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 , some for PtdIns(3,4,5)P 3 only and some for PtdIns(3,4)P 2 only (Table 2) . PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 exhibit subtly different time courses of accumulation when they have been measured accurately.
It is important to note that the drive to understand how Class I PI3Ks function and the discovery of the PH domain as a major 'transducer' of PtdIns(3,4,5)P 3 signals sets an important paradigm for how other phosphoinositides might exert regulating roles in cells, and this contributed greatly The serine/threonine protein kinase PKB (also known as Akt), is a major effector of the Class I PI3K signalling pathway. It is activated by PI3K-dependent phosphorylation in the activation loop of the kinase domain (Thr 308 in human PKBα) and in the C-terminus (Ser 473 in human PKBα). Generation of Class I PI3K-dependent PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 leads to recruitment of PKB to the membrane and a conformational switch allowing Thr 308 to be phosphorylated by PDK. PDK, a serine/threonine kinase, is responsible for non-PI3K-dependent phosphorylation of several AGC family kinases [36] ; it also possesses a PtdIns(3,4,5)P 3 -binding PH domain that may promote more efficient phosphorylation of PKB in PtdIns(3,4,5)P 3 -rich areas of the membrane [35] . Studies have demonstrated a wortmannin-sensitive [78] PtdIns(3,4,5)P 3 -dependent [79] phosphorylation of Ser 473 . The exact role of PtdIns(3,4,5)P 3 in this process remains unclear, although it is independent of PDK1 [78, 80] . Recent data have described that direct phosphorylation of Ser 473 can be carried out by a rapamycin-insensitive form of mTORC2 [and also possibly by DNA-dependent protein kinase (DNAPK)], while Ser 473 is dephosphorylated by the PH domain leucine-rich repeat protein phosphatase (PHLPP), although details of how this is regulated are still unclear [80] .
Phosphorylation of Ser 473 appears to act as a 'gain control' for PKB, regulating the degree of activation of PKB once Thr 308 has been phosphorylated by PDK.
to the discoveries of several other phosphoinositide-binding domains, including other subfamilies of PH domains, which are now accepted to play key roles in phosphoinositidemediated regulation [39, 40] (Table 2 ). The general picture that has emerged is that synthesis of phosphoinositides in a particular membrane location can act as a type of 'regulatable scaffold' which can influence, through their possession of the appropriate phosphoinositide-binding domains, the complement of peripheral membrane-binding proteins which participate in events at this location. For example, synthesis of PtdIns3P by Class III PI3K in endosomal locations plays a key role in recruiting several proteins containing PtdIns3P-specific FYVE or PX (phox homology) domains which are involved in vesicle docking and protein sorting at this location [4] . It should be noted, however, that, although being pervasive, phosphoinositide binding often occurs in concert with other regulatory events (e.g. binding of small GTPases) to ensure appropriate specificity is retained at a particular membrane location.
Class I PI3Ks regulate several important cell responses
The many different effectors of PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 fall into several protein classes ( Figure 8 , Table 2 ). As stated Table 2 Examples of common phosphoinositide recognition domains ANTH, AP180 N-terminal homology; AP2α, activator protein 2α; AP180, assembly protein 180; DAPP1, dual adaptor for phosphotyrosine and 3-phosphoinositides 1; EEA1, early endosome antigen 1; ENTH, epsin N-terminal homology; FAPP1, PtdIns-four-phosphate adaptor protein 1; FERM, four-point-one, ezrin, radixin, moesin; OSBP, oxysterol-binding protein; PHD, plant homeodomain; PLC, phospholipase; SNX-3, sorting nexin 3; TAPP1, tandem PH-domain-containing protein 1. See also [39, 40, 75, 85, 86] . above, this creates a highly complex signalling web downstream of Class I PI3K activation which allows different levels of influence on many different cellular responses. These responses are diverse and can be cell-context-specific, e.g. insulin-stimulated glucose uptake in adipocytes [41] , IgE-stimulated histamine secretion in mast cells [42] or fMLPstimulated NADPH oxidase activation in neutrophils [43] . Other PI3K-dependent responses, however, seem to be quite common across a variety of different contexts. One intensely studied area is the role of Class I PI3Ks in the control of cell movement and, in particular, the formation of membrane protrusions, or lamellipodia [44] [45] [46] . Here, production of PtdIns(3,4,5)P 3 /PtdIns(3,4)P 2 is thought to regulate the activity of several GEFs and GAPs (GTPaseactivating proteins) which regulate the activity cycle of Arf and Rac GTPases, which in turn are key regulators of the cytoskeletal and membrane delivery events which are thought to underlie these processes, although a coherent understanding of how PI3Ks regulate lamellipodia formation is still some way off.
Another major area of Class I PI3K-dependent regulation is based on the general observation that growth-factorreceptor-stimulated Class I PI3Ks provide an overall positive input into increases in cell growth, proliferation and survival. Recent evidence indicates that PI3K-dependent activation of PKB plays a central role in these events [47] [48] [49] [50] [51] [52] (Figure 11 ). PKB appears to be universally activated in response to activation of Class I PI3K and indeed phosphorylation of PKB at its key activating residues (Thr 308 or Ser 473 ) has become, probably unwisely, synonymous with increased Class I PI3K activity. PKB has been shown to play multiple roles in cellular regulation: it has been shown to have a significant input into activating mTORC1 (mammalian target of rapamycin complex 1) [via de-repression of the hTSC1/TSC2 (TSC is tuberous sclerosis complex)], a key integrator of cellular growth decisions; it is a major regulator of the FOXO (Forkhead box O) family of transcription factors (via protein 14-3-3-mediated cytosolic sequestration), and also p27 KIP and GSK3 (glycogen synthase kinase 3), all key regulators of cell-cycle progression and survival. The importance of the PI3K/PKB axis to the control of cell growth, survival and proliferation is clear from the number of important oncogenic mutations found in components of this pathway (Figure 11 ). This appears to be an important and evolutionarily conserved role for PI3K signalling, since this pathway also plays an important role in the regulation of cell growth in lower organisms and this may indeed have been the original function of this pathway as it first developed [47] .
Signalling through specific Class I PI3K isoforms offers the possibility of novel therapeutic intervention
It is clear from the work establishing the mechanism and function of the Class I PI3K signalling pathway that this pathway must inevitably control elements of cellular function that are relevant to areas of drug discovery. This is particularly clear in areas of cell growth and proliferation relevant to cancer [47, 53] . Furthermore, the complexity which exists ERK, extracellular-signal-regulated kinase; FOXO, Forkhead box O; GSK3, glycogen synthase kinase 3; HIF1, hypoxia-inducible factor 1; IKK, inhibitory κB kinase; Mdm2, murine double minute 2; mTOR, mammalian target of rapamycin; NF1, nuclear factor 1; NF-κB, nuclear factor κB; PFK2, 6-phosphofructose-2-kinase; PHLPP, PH domain leucine-rich repeat protein phosphatase; RTK, receptor tyrosine kinase; S6K, S6 kinase; TSC, tuberous sclerosis complex. See recent reviews for primary references [47] [48] [49] [50] [51] [52] .
in the structure of the various Class I PI3K isoforms indicates that some may play specific non-redundant roles in relevant physiological pathways, opening up the possibility for specific therapeutic interventions. In the last few years, the development of several mouse models which are deficient in signalling through one or more regulatory or catalytic subunits of Class I PI3Ks [54] (summarized in Table 3 ) has confirmed this as a promising approach providing the impetus to both academic and pharmaceutical scientists to investigate the plausibility for designing PI3K isoform-selective inhibitors [55] . The early discovery of wortmannin, a fungal metabolite which is a potent, cell-permeable inhibitor of PI3Ks [56] , offered an important clue that the ATP-binding site of PI3Ks might be a very 'druggable' target. Through a combination of high-throughput screening and molecular modelling [57] , the first molecules with significant isoformselectivity against specific Class I PI3K isoforms are being characterized [55] . Lead compounds are in clinical trials in several drug companies, and the results are awaited with interest, but several useful compounds are already available in the public domain (summarized in Table 4 ). The use of these compounds, often in conjunction with the relevant mouse transgenic model (to control for potential off-target effects) is certain to rapidly improve our knowledge of the specific roles of Class I PI3K isoforms in mammalian physiology.
The initial observations that p110γ and p110δ expression was relatively restricted to myeloid-derived cells suggested that these isoforms would have particularly important roles in Class I PI3K signalling in these cell types. The recent characterization of transgenic mice lacking p110γ and p110δ catalytic activity, which are viable but with specific defects in leucocyte, lymphocyte and mast cell function, have confirmed this [54, 58, 59] . As expected, p110γ plays a major role in the synthesis of PtdIns(3,4,5)P 3 downstream of G icoupled receptors in granulocytes and regulates both their homing to sites of inflammation and their activities [19] [20] [21] (e.g. production of extracellular NADPH oxidase-dependent reactive oxygen metabolites). Thus p110γ appears to be an interesting target for novel anti-inflammatory therapeutics and this promise appears to be borne out by the efficiency of recently developed p110γ -specific inhibitors in models of rheumatoid arthritis [60] . Several recent studies have suggested that PI3Kγ and PI3Kδ are often activated in parallel or sequentially downstream of receptor activation [62] [63] [64] (e.g. in neutrophils downstream of G-protein-coupled receptors, or mast cells downstream of IgE and adenosine receptors) suggesting that combinatorial inhibition of these PI3K isoforms may prove useful. Little is yet known of the specific role of PI3Kβ in receptor signalling pathways, but the recent development of p110β-selective inhibitors suggests that they may be useful in anti-thrombotic therapy [65] .
The recent discovery that p110α mutations are remarkably common in many different human tumours [47, 66] and that these mutations are activating in the absence of receptor stimulation [8, 9] has created a great deal of excitement as to the possibility that specific inhibition of p110α might represent a useful anticancer therapy [53] . p110α −/− or p110α KD/KD (kinase dead) mice have a block in early embryonic development, indicative of a widespread role for PI3Kα in the signalling mechanisms of several receptor types [54] . p110α KD/+ heterozygotes, however, have measurable phenotypes in cell growth and glucose homoeostasis, indicating specific roles for p110α in insulin-and growth-factor-dependent signalling pathways [67] , confirmed by the use of p110α-selective inhibitors [55] . p110α-selective inhibitors may have widespread unwanted side effects in several different tissues, but, until this is investigated further, the extent of this problem is unknown; furthermore there is the potential for the development of inhibitors selective for the common oncogenic forms of p110α [68] .
